Effet de l'almitrine per os sur le syndrome d'apnée du sommeil [Effect of oral almitrine on the sleep apnea syndrome].

Détails

ID Serval
serval:BIB_CCD071A6F1BE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Effet de l'almitrine per os sur le syndrome d'apnée du sommeil [Effect of oral almitrine on the sleep apnea syndrome].
Périodique
Revue Française des Maladies Respiratoires
Auteur(s)
Mangin P., Krieger J., Kurtz D.
ISSN
0301-0279 (Print)
ISSN-L
0301-0279
Statut éditorial
Publié
Date de publication
1983
Volume
11
Numéro
6
Pages
899-906
Langue
français
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Almitrine stimulates breathing by activating peripheral chemoreceptors and was given orally in a dose of 200 mg/day to nine patients with sleep apnoea syndrome, after a single blind placebo sequence. No reduction in the number of respiratory events per hour of sleep was observed. On the other hand Almitrine led to a significant fall in the mean duration of respiratory events (p less than 0.02). This fall occurred principally in the obstructive apnoea group and in those with mixed apnoea only during light slow wave sleep. These results are in agreement with the hypothesis that the arousal response to hypoxia mediated by the chemoreceptors could be responsible for the termination of sleep apneas.
Mots-clé
Aged, Almitrine, Central Nervous System Stimulants/therapeutic use, Chemoreceptor Cells/physiology, Humans, Male, Middle Aged, Piperazines/therapeutic use, Respiration, Sleep Apnea Syndromes/drug therapy, Sleep Apnea Syndromes/physiopathology, Sleep Stages/physiology
Pubmed
Création de la notice
11/10/2010 16:35
Dernière modification de la notice
20/08/2019 16:47
Données d'usage